SUN GLOBAL
SUN GLOBAL
Factory direct peptide supply
Dual GIP/GLP-1 Receptor Agonist
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. This 39-amino acid peptide represents a significant advancement in metabolic research, combining the actions of two incretin hormones. Our tirzepatide is synthesized using advanced SPPS technology with C18 fatty acid conjugation for extended half life.
For faster quotation, include purity, quantity, packaging request and target market.
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. This 39-amino acid peptide represents a significant advancement in metabolic research, combining the actions of two incretin hormones. Our tirzepatide is synthesized using advanced SPPS technology with C18 fatty acid conjugation for extended half-life.
Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Ala-Met-Asp-Lys-Ile-His-Gln-Gln-Asp-Phe-Val-Asn-Trp-Leu-Leu-Ala-Gln-Lys-Gly-Lys-Lys-Asn-Asp-Trp-Lys-His-Asn-Ile-Thr-Gln-NH₂
Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Ala-Met-Asp-Lys-Ile-His-Gln-Gln-Asp-Phe-Val-Asn-Trp-Leu-Leu-Ala-Gln-Lys-Gly-Lys-Lys-Asn-Asp-Trp-Lys-His-Asn-Ile-Thr-Gln-NH₂
Batch-specific testing results
Factory supply workflow
Send the product name, selected strength, quantity, purity requirement, packaging style and destination market. The sales team can confirm stock, MOQ, batch COA, HPLC/MS files, lead time and private label options.
Product name, mg/vial, vial count and target quantity.
Batch COA, HPLC, MS, appearance and storage conditions.
Factory price, MOQ, label, box and custom brand support.
Fast preparation with export support and shipment updates.
Peer-reviewed scientific literature on Tirzepatide from PubMed, NEJM, The Lancet, and other authoritative sources.
Jastreboff AM, Aronne LJ, Ahmad NN, et al.
New England Journal of Medicine, 387: 205–216 (2022)
Participants receiving tirzepatide 15 mg reported substantial body-weight change versus placebo in a phase 3 metabolic research trial.
Frias JP, Davies MJ, Rosenstock J, et al.
New England Journal of Medicine, 385: 503–515 (2021)
All tirzepatide doses showed superior HbA1c reductions compared to semaglutide 1 mg. Tirzepatide 15 mg reduced HbA1c by 2.46% vs. 1.86% for semaglutide (p<0.001), with greater weight loss (−11.2 kg vs. −5.3 kg).
Min T, Bain SC.
Drugs, 81: 1905–1918 (2021)
The synergistic activation of both GIP and GLP-1 receptors by tirzepatide produces additive metabolic benefits beyond either pathway alone, explaining its superior efficacy compared to selective GLP-1 agonists.
